Amarin Corporation PLC Announces Additional Vascepa® (icosapent ethyl) Supplier

Published: Dec 11, 2012

BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, today announced the addition of an exclusive consortium of companies led by Slanmhor Pharmaceutical, Inc. (Slanmhor) to its planned active pharmaceutical ingredient (API) global supply chain for Vascepa® (icosapent ethyl) capsules. Slanmhor was spun-out from Ocean Nutrition Canada (ONC) prior to the May 2012 acquisition of ONC by Royal DSM N.V. (DSM), a global leader in life sciences and materials sciences. Amarin now has a total of four API suppliers for Vascepa API for Amarin to utilize to support the global commercialization of Vascepa, subject to appropriate regulatory approvals.

Back to news